Actinium Pharmaceuticals will showcase ATNM-400's preclinical efficacy in therapy-resistant breast cancer at the upcoming SABCS 2026, emphasizing its potential across various cancers.

Actinium Pharmaceuticals (ATNM) will feature its first-in-human Phase 1 study of ATNM-400 at ESMO 2026, held October 23–27 in Madrid. The investigational radiotherapy targets HER3 rather than PSMA in metastatic castration-resistant prostate cancer, disease that has spread and resists testosterone-lowering treatment.The study combines Zirconium-89-labeled imaging with Actinium-225 treatment to assess safety and establish a recommended Phase 2 dose. Patients with positive imaging proceed to treatment every six weeks for up to four cycles. Enrollment includes patients with and without prior PSMA-directed therapy. Initial imaging results showed tumor uptake and retention through Day 7; the company described initial tolerability as encouraging. The ESMO presentation is a trial-in-progress ePoster, with additional study assessments covering radiation exposure, drug behavior in the body and antitumor activity.

Actinium Pharmaceuticals has unveiled promising preclinical results for ATNM-400 at EANM 2026, highlighting its effectiveness across various cancers.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced en...

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Actinium Pharmaceuticals showcased promising results for ATNM-400, a novel HER3-targeted radiotherapy, showing strong initial safety and efficacy data in prostate cancer treatment at EANM 2026.

Reported Tuesday, Oct 20 - 8:07am EDT (TheFly subscription required to read more.)

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced ne...

Actinium Pharmaceuticals presented groundbreaking data for ATNM-400, targeting prostate and lung cancers at EANM 2026, showcasing its potential across various tumors.

Actinium Pharmaceuticals (ATNM) will present early clinical and preclinical ATNM-400 data at the European Association of Nuclear Medicine congress on October 19, 2026.The clinical presentation covers an ongoing first-in-human Phase 1 dose-escalation study in metastatic castration-resistant prostate cancer. It will describe evaluation of a Zirconium-89-labeled imaging counterpart, including safety, distribution in the body, radiation dosing and PET imaging, to inform development and dosing of Actinium-225-labeled ATNM-400.The preclinical presentation covers KRAS- and ALK-driven non-small cell lung cancer models, evaluating ATNM-400 alone and with KRAS or ALK inhibitors. Actinium is developing the investigational HER3-targeted radiotherapy for use alone and in combinations across multiple solid tumors. Both presentations are scheduled for 4:45–6:15 p.m. CEST in Vienna.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today reminded inv...

At EANM 2026, Actinium Pharmaceuticals unveils groundbreaking findings on ATNM-400's antitumor potential across various cancer models, indicating significant advancements in treatment.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced th...

Reported Friday, Oct 16 - 8:32am EDT (TheFly subscription required to read more.)

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Actinium Pharmaceuticals announced exciting early findings from a Phase 1 trial of ATNM-400 at EANM 2026, marking a potential breakthrough in prostate cancer treatment.

Actinium Pharmaceuticals (ATNM) will present early results from its first-in-human Phase 1 ATNM-400 prostate cancer study at EANM on October 19, 2026.The ongoing dose-escalation study involves metastatic castration-resistant prostate cancer, cancer that has spread and resists testosterone-lowering treatment. It evaluates Zirconium-89-labeled ATNM-400 for safety, distribution in the body and radiation exposure. Repeated PET scans will assess tumor uptake, distribution and clearance, with radiation-dose estimates informing dosing of the Actinium-225-labeled therapy. ATNM-400 targets an antigen other than PSMA. Actinium said the early clinical data support advancing the program, which is being developed for patients including those with low or absent PSMA and those whose disease does not respond to or progresses after PSMA-directed therapies.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced th...